Learn about the effectiveness of tumor-targeted T cell immunotherapy from our patients.
Mr. He is an 80 years old man, seeing his great grandson is one of his several wishes at his late age. But the recurrence and metastasis of the stomach cancer make this wish seem so far away.
In May 2007, Mr. He was diagnosed with stomach cancer, but it was fortunate that it did not metastasize, surgery would be the first treatment option. Although at the age of 75, Mr. He’s overall health condition was well except having stomach cancer, he chose to receive surgery followed with four rounds of chemotherapy. Read more
A 48 years old female Chinese patient was diagnosed with lymphoma.
After receiving treatment with DC-CTL cancer immunotherapy (dendritic cell and T cell), the PET/CT scan showed that the metabolic activity of the lymph nodes on supraclavicular, mediastinal and pulmonary hilum were significantly reduced. Read more
Two weeks after the immunotherapy with cytokine-induced killer cells (CIK), the comparison value of CD3+, CD4+T cells, NK (Natural Killer) cells and CD4+/CD8+ significantly increased compare with the pre-treatment status, and the value continues to increase with the time being, 2 – 4 weeks after the cancer immunotherapy, this value reached its peak point, after this point, the level of the patient’s immune response declines. 8 weeks after the CIK immunotherapy, the value of CD3+, CD4+T cells, NK cells and CD4+/CD8+ in the peripheral blood declined to a lower level, but the value maintains higher than the control group.